Soligenix (SNGX) Expected to Announce Quarterly Earnings on Tuesday

Soligenix (NASDAQ:SNGX) is expected to release its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect Soligenix to post earnings of ($0.27) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, April 1, 2026 at 4:00 PM ET.

Soligenix Price Performance

Soligenix stock opened at $1.21 on Tuesday. Soligenix has a 12 month low of $1.02 and a 12 month high of $6.23. The company has a fifty day moving average price of $1.22 and a two-hundred day moving average price of $1.49. The company has a market cap of $12.21 million, a PE ratio of -0.34 and a beta of 1.99.

Institutional Investors Weigh In On Soligenix

Several large investors have recently made changes to their positions in SNGX. XTX Topco Ltd bought a new stake in shares of Soligenix during the fourth quarter valued at approximately $37,000. StoneX Group Inc. bought a new position in Soligenix in the 4th quarter worth approximately $50,000. Jane Street Group LLC acquired a new stake in Soligenix in the 4th quarter valued at approximately $51,000. Banco BTG Pactual S.A. acquired a new stake in Soligenix in the 3rd quarter valued at approximately $54,000. Finally, Virtu Financial LLC bought a new stake in Soligenix during the 3rd quarter valued at $59,000. Institutional investors and hedge funds own 3.60% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Soligenix in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Soligenix currently has an average rating of “Hold” and a consensus target price of $6.00.

About Soligenix

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.